Improving heart function in donor hearts for transplantation
Targeting Immune-Responsive Gene 1 (Irg1) and Itaconate for Cardioprotection of the Donor Heart for Transplantation
['FUNDING_R01'] · MAYO CLINIC ROCHESTER · NIH-10906125
This study is looking at how a medication called valproic acid might help make donor hearts work better after a transplant, which could lead to better results for people receiving heart transplants.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-10906125 on ClinicalTrials.gov |
What this research studies
This research investigates how to enhance the function of donor hearts used in transplants, particularly focusing on a drug called valproic acid (VPA). VPA is known for treating epilepsy but has shown promise in improving heart function by increasing the production of a protective metabolite called itaconate. The study uses animal models to explore how VPA can help prevent primary graft dysfunction, a condition that affects 10-20% of transplant patients. By improving the preservation of donor hearts, this research aims to enhance outcomes for heart transplant recipients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals awaiting heart transplantation or those who have received a donor heart.
Not a fit: Patients who are not candidates for heart transplantation or those with contraindications to valproic acid may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better heart transplant outcomes and reduced complications for patients.
How similar studies have performed: Previous studies have shown that enhancing donor heart preservation can significantly improve transplant outcomes, indicating a promising avenue for this research.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TANG, PAUL — MAYO CLINIC ROCHESTER
- Study coordinator: TANG, PAUL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.